BioSpace News Archive

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced topline data from its phase 2 REDIRECT study investigating AFM13 monotherapy in patients with advanced-stage r/r PTCL.

AbbVie announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.

Incyte announced new data from two of its LIMBER trials evaluating monotherapy and combination strategies using ruxolitinib with parsaclisib, its investigational phosphatidylinositol 3-kinase delta inhibitor, and INCB00928, its activin receptor-like kinase inhibitor, in patients with myelofibrosis.

Centessa Pharmaceuticals plc, announced new data from an additional 18-months of continued treatment with SerpinPC, an investigational, subcutaneously administered novel inhibitor of activated protein C, from the open-label extension of the Phase 2a study of SerpinPC for hemophilia.

Servier presented new data at the 64th Annual Meeting of the American Society of Hematology characterizing clonal evolution and relapse mechanisms in patients with newly-diagnosed IDH1-mutated acute myeloid leukemia who are 75 years of age or older or have comorbidities that preclude use of intensive induction chemotherapy treated with TIBSOVO in combination with azacitidine.

Sumitomo Pharma Oncology, Inc. presented new data from the ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM1 kinase inhibitor, in patients with myelofibrosis previously treated with or ineligible for JAK inhibitor therapy.

Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced the clinical data from its ongoing Phase 1, investigator-initiated trial in China evaluating FasTCAR-enabled GC012F as first-line therapy in transplant-eligible, high-risk, newly diagnosed multiple myeloma patients.

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the updated preliminary data from a Phase I study of tifcemalimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas in a poster at the 64th American Society of Hematology Annual Meeting.

LAVA Therapeutics N.V. announced a poster presentation highlighting updated data, including safety, pharmacodynamics and pharmacokinetics from the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsing/refractory chronic lymphocytic leukemia and multiple myeloma at the 64th American Society of Hematology Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10–13, 2022.

AltruBio Inc. announced the presentation of new data from its completed Phase 1b clinical trial evaluating ALTB-168 in patients with steroid-refractory or treatment-refractory acute graft-versus-host-disease at the 64th American Society of Hematology Annual Meeting, taking place December 10-13, 2022 in New Orleans, La.